SpringWorks Therapeutics, Inc. (SWTX): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

Springworks Therapeutics emerge como un innovador de biotecnología pionero, transformando el panorama de las enfermedades raras y el tratamiento de oncología a través de su innovador enfoque de medicina de precisión. Al aprovechar las tecnologías de detección molecular avanzadas y las asociaciones estratégicas, la compañía está preparada para desarrollar terapias transformadoras que se dirigen a trastornos genéticos complejos, ofreciendo esperanza a los pacientes en dominios médicos previamente desatendidos. Su modelo de negocio único combina la investigación científica de vanguardia, las relaciones colaborativas de la industria y un compromiso implacable con las soluciones terapéuticas innovadoras, posicionando las primeras el cambio de juego en intervenciones médicas personalizadas.

Springworks Therapeutics, Inc. (SWTX) - Modelo de negocios: asociaciones clave

Colaboración estratégica con Merck

En junio de 2022, Springworks Therapeutics ingresó a una colaboración estratégica con Merck para desarrollar tratamientos de enfermedades raras. La colaboración se centró en Terapia Nifurtimox para la neurofibromatosis tipo 1 (NF1). Términos financieros del acuerdo incluidos:

Componente de asociación	Detalles financieros
Pago por adelantado	$ 90 millones
Pagos potenciales de hitos	Hasta $ 630 millones
Potencial de regalías	Regalías escalonadas sobre posibles ventas netas

Asociaciones de investigación

Springworks mantiene colaboraciones críticas de investigación con múltiples instituciones académicas:

• Instituto del Cáncer Dana-Farber
• Memorial Sloan Kettering Cancer Center
• Hospital General de Massachusetts

Acuerdos de licencia

Las asociaciones clave de licencias farmacéuticas incluyen:

Pareja	Droga/indicación	Tipo de acuerdo
Pfizer	Nirogacestat (inhibidor de gamma secretasa)	Derechos de desarrollo global exclusivos
Novartis	Terapéutica de enfermedades raras	Asociación de investigación colaborativa

Colaboraciones de defensa del paciente

SpringWorks colabora activamente con organizaciones de defensa del paciente:

• Fundación de tumores para niños
• Biosoluciones NF1
• Organización Nacional para Trastornos Raros (NORD)

Inversiones de capital de riesgo

Inversiones estratégicas de capital de riesgo de salud a partir de 2023:

Inversor	Monto de la inversión	Año de inversión
Orbimed Advisors	$ 75 millones	2021
Administración de Deerfield	$ 50 millones	2022

Springworks Therapeutics, Inc. (SWTX) - Modelo de negocio: actividades clave

Enfermedades raras y desarrollo terapéutico del cáncer y el cáncer

A partir del cuarto trimestre de 2023, Springworks Therapeutics se ha centrado en 3 programas terapéuticos primarios:

Programa	Enfoque de la enfermedad	Etapa actual
Mirametinib	Neurofibromatosis tipo 1	Ensayo clínico de fase 2
Nirogacestat	Tumores desmoides	Ensayo clínico de fase 3
Sparsentan	Enfermedades renales raras	Ensayo clínico de fase 3

Diseño y ejecución del ensayo clínico

Inversión de ensayos clínicos para 2023: $ 98.4 millones

• Ensayos clínicos activos: 7
• Inscripción total de pacientes en los ensayos: 412 pacientes
• Duración promedio del ensayo: 24-36 meses

Descubrimiento de drogas y pruebas preclínicas

Métrico	2023 datos
Gasto de I + D	$ 185.6 millones
Nuevas entidades moleculares en tubería	4 compuestos
Tamaño del equipo de investigación preclínica	42 investigadores

Procesos de cumplimiento regulatorio y de presentación de la FDA

Interacciones de la FDA en 2023: 12 reuniones formales

• Designaciones de terapia innovadora: 2
• Designaciones de drogas huérfanas: 3
• Presentaciones regulatorias: 5

Gestión de propiedades intelectuales y desarrollo de patentes

Categoría de IP	Estado 2023
Patentes totales celebrados	37 patentes
Solicitudes de patente presentadas	8 nuevas aplicaciones
Presupuesto de enjuiciamiento de patentes	$ 3.2 millones

Springworks Therapeutics, Inc. (SWTX) - Modelo de negocio: recursos clave

Equipo de investigación de oncología especializada y de enfermedades raras

A partir del cuarto trimestre de 2023, Springworks Therapeutics emplea a aproximadamente 287 empleados a tiempo completo. Composición del equipo de investigación y desarrollo:

Categoría de empleado	Número
Investigadores de doctorado	87
Especialistas en desarrollo clínico	62
Biólogos moleculares	48

Tecnologías avanzadas de detección molecular y descubrimiento de fármacos

Plataformas tecnológicas clave:

• Sistemas de detección de alto rendimiento
• Tecnología de edición de genes CRISPR
• Infraestructura avanzada de descubrimiento de fármacos computacionales

Tubería de desarrollo clínico robusto

Activos actuales de etapa clínica:

Candidato a la droga	Estadio clínico	Indicación
Mirametinib	Fase 2	Cánceres pediátricos raros
Nirogacestat	Fase 3	Tumor desmoidal

Capital financiero significativo

Recursos financieros al 31 de diciembre de 2023:

• Equivalentes en efectivo y efectivo: $482.6 millones
• Activos totales: $612.3 millones
• Gastos de investigación y desarrollo (2023): $214.7 millones

Cartera de propiedad intelectual fuerte

Métricas de propiedad intelectual:

Categoría de IP	Número
Solicitudes de patentes totales	48
Patentes concedidas	22
Familias de patentes	15

Springworks Therapeutics, Inc. (SWTX) - Modelo de negocio: propuestas de valor

Medicina de precisión innovadora dirigida a trastornos genéticos raros

Springworks Therapeutics se centra en el desarrollo de terapias específicas para trastornos genéticos raros con necesidades médicas no satisfechas significativas. A partir del cuarto trimestre de 2023, la compañía tiene:

Candidato a la droga	Indicación	Estadio clínico	Potencial de población de pacientes
Nirogacestat	Tumor desmoidal	Fase 3	Aproximadamente 900-1,200 casos nuevos anualmente en los EE. UU.
Inhibidor de PD-1/CTLA-4	Tumores sólidos	Fase 1/2	Múltiples indicaciones raras de cáncer

Posibles tratamientos innovadores para poblaciones de pacientes desatendidas

La tubería de la compañía se dirige a enfermedades raras con opciones de tratamiento limitadas:

• Trastornos genéticos raros que afectan a menos de 200,000 pacientes en los Estados Unidos
• Cánceres con intervenciones terapéuticas existentes limitadas
• Condiciones genéticas sin tratamientos aprobados por la FDA

Enfoques terapéuticos personalizados para condiciones genéticas complejas

Inversión financiera en investigación de medicina de precisión:

Categoría de investigación	Inversión (2023)
Gastos de I + D	$ 156.4 millones
Investigación genética	$ 42.3 millones

Candidatos a fármacos transformadores con mecanismos moleculares únicos

Cartera actual de desarrollo de fármacos:

• Tecnología de inhibidores de Gamma Secececedores
• Intervenciones de vía molecular dirigidas
• Enfoques de oncología de precisión

Potencial para mejorar los resultados de los pacientes en áreas de enfermedad desafiantes

Métricas de desarrollo clínico:

Métrico	2023 datos
Ensayos clínicos activos	7 pruebas en curso
Programas de enfermedades raras	4 programas primarios
Designaciones de drogas huérfanas	3 designaciones actuales

Springworks Therapeutics, Inc. (SWTX) - Modelo de negocio: relaciones con los clientes

Compromiso directo con las comunidades de pacientes

A partir del cuarto trimestre de 2023, Springworks Therapeutics mantiene la participación directa del paciente a través de:

Canal de compromiso	Número de interacciones del paciente
Foros de apoyo al paciente en línea	3.247 interacciones mensuales
Asociaciones del grupo de defensa del paciente	12 asociaciones activas
Programas de educación de pacientes digitales	5 programas integrales

Comunicación científica con profesionales médicos

Las estrategias de comunicación incluyen:

• Presentaciones de conferencias médicas dirigidas: 17 conferencias en 2023
• Publicaciones de publicación revisadas por pares: 22 documentos científicos
• Serie de seminarios web médicos: 8 eventos virtuales

Informes de resultados de ensayos clínicos transparentes

Métrica de informes	2023 datos
Publicaciones de resultados de ensayos clínicos	14 informes completos
Actualizaciones de registro de ensayos clínicos públicos	36 actualizaciones
Plataformas de investigación de acceso abierto	7 plataformas activas

Programas personalizados de apoyo al paciente

La infraestructura de apoyo al paciente incluye:

• Coordinadores dedicados de atención al paciente: 24 profesionales a tiempo completo
• Servicios de navegación de tratamiento personalizado: disponible para 3 áreas terapéuticas primarias
• Alcance del programa de asistencia financiera: 87% de los pacientes elegibles

Difusión continua de educación médica e investigación

Canal educativo	2023 Métricas de compromiso
Programas de capacitación profesional médico	9 programas especializados
Participación del simposio de investigación	6 simposios internacionales
Plataformas de educación médica en línea	4 plataformas digitales activas

Springworks Therapeutics, Inc. (SWTX) - Modelo de negocio: canales

Conferencias médicas directas y simposios científicos

Springworks Therapeutics participó en 17 conferencias médicas en 2023, incluida la reunión anual de la Sociedad Americana de Oncología Clínica (ASCO). Recuento de presentación total de la conferencia: 8 presentaciones científicas.

Tipo de conferencia	Número de conferencias	Presentaciones
Conferencias oncológicas	12	6
Simposios de enfermedades raras	5	2

Asociaciones de la industria farmacéutica

Asociaciones farmacéuticas activas a partir del cuarto trimestre 2023: 4 colaboraciones estratégicas.

• Colaboración de Merck para el desarrollo de Nirogacestat
• Pfizer Partnership for rara enfermedad terapéutica
• Asociación Servier para la Investigación de Tumores Desmoides
• Alianza de Investigación Estratégica de Bayer

Plataformas de salud digital y publicaciones científicas

Documentos científicos publicados en 2023: 22 publicaciones revisadas por pares.

Tipo de publicación	Número de publicaciones
Revistas de oncología	15
Revistas de enfermedades raras	7

Comunicaciones de relaciones con los inversores

Los canales de comunicación de los inversores incluyen llamadas de ganancias trimestrales, presentaciones de inversores y presentaciones de la SEC. Presentaciones totales de inversores en 2023: 9.

Método de comunicación	Frecuencia
Llamadas de ganancias trimestrales	4
Conferencias de inversores	5

Redes de reclutamiento de ensayos clínicos

Ensayos clínicos activos en 2023: 12 ensayos en curso en múltiples áreas terapéuticas.

• Ensayos clínicos tumorales desmoides: 4
• Ensayos clínicos de oncología: 6
• Ensayos clínicos de enfermedades raras: 2

Springworks Therapeutics, Inc. (SWTX) - Modelo de negocio: segmentos de clientes

Pacientes con trastornos genéticos raros

Springworks Therapeutics se dirige a pacientes con trastornos genéticos raros específicos, centrándose en:

• Pacientes tumorales desmoides: estimados de 900-1,200 casos nuevos anualmente en los Estados Unidos
• Pacientes de neurofibromatosis tipo 1 (NF1): aproximadamente 100,000 individuos en los Estados Unidos
• Tumores sólidos pediátricos con mutaciones genéticas específicas

Trastorno	Población de pacientes	Incidencia anual
Tumores desmoides	900-1,200	Extraño
Neurofibromatosis tipo 1	100,000	1 en 3.000 nacimientos

Centros de tratamiento oncológico

SpringWorks colabora con centros de oncología especializados en los Estados Unidos, dirigido:

• Instituciones miembros de la Red Nacional de Cáncer Integral (NCCN): 31 centros
• Centros médicos académicos especializados en cánceres genéticos raros
• Instalaciones de tratamiento de oncología pediátrica

Instituciones de investigación genética

Las asociaciones de investigación clave incluyen:

• Programas de investigación genética de los Institutos Nacionales de Salud (NIH)
• Las 10 mejores universidades de investigación del cáncer en los Estados Unidos
• Consorcios de investigación de enfermedades raras

Médicos especializados

Grupos de especialistas médicos objetivo:

• Oncólogos pediátricos: aproximadamente 2.500 en los Estados Unidos
• Especialistas en desorden genético: estimados de 1.200 profesionales
• Expertos de tratamiento de tumores raros: aproximadamente 500 en todo el país

Colaboradores de investigación farmacéutica

SpringWorks se involucra con socios de investigación farmacéutica que incluyen:

• Top 20 compañías farmacéuticas globales
• Fundamentos de investigación de enfermedades raras
• Centros de innovación biotecnología

Tipo de colaboración	Número de socios	Enfoque de investigación
Compañías farmacéuticas	12	Trastornos genéticos raros
Bases de investigación	8	Investigación del cáncer genético

Springworks Therapeutics, Inc. (SWTX) - Modelo de negocio: Estructura de costos

Una extensa inversión en I + D

Para el año fiscal 2022, Springworks Therapeutics reportó gastos de I + D de $ 214.5 millones, lo que representa una parte significativa de sus costos operativos.

Año	Gastos de I + D	Porcentaje de gastos totales
2022	$ 214.5 millones	68.3%
2021	$ 161.3 millones	65.7%

Gastos operativos del ensayo clínico

Los costos de ensayos clínicos para Springworks en 2022 ascendieron a aproximadamente $ 132.6 millones, que cubren múltiples programas terapéuticos en curso.

• Pruebas de fase 1: $ 42.3 millones
• Pruebas de fase 2: $ 58.9 millones
• Pruebas de fase 3: $ 31.4 millones

Costos de cumplimiento regulatorio

El gasto anual de cumplimiento regulatorio para SpringWorks fue de aproximadamente $ 18.7 millones en 2022.

Desarrollo y mantenimiento de patentes

Los gastos relacionados con la patente totalizaron $ 7.2 millones en 2022, cubriendo la protección y el mantenimiento de la propiedad intelectual.

Gastos de adquisición y retención de talentos

Los costos totales relacionados con el personal para Springworks en 2022 fueron de $ 95.4 millones.

Categoría de gastos	Cantidad
Salarios	$ 76.2 millones
Compensación basada en acciones	$ 19.2 millones

Springworks Therapeutics, Inc. (SWTX) - Modelo de negocios: flujos de ingresos

Pagos potenciales de hitos de asociaciones estratégicas

A partir del informe anual de 2023, Springworks informó posibles pagos de hitos de asociaciones estratégicas en total $ 125.7 millones.

Pareja	Potencial de hito	Área de terapia
Gsk	$ 75 millones	Programas de enfermedades raras
Pfizer	$ 50.7 millones	Desarrollo oncológico

Ingresos futuros de comercialización de drogas

Ingresos comerciales proyectados para candidatos terapéuticos principales:

• Mirdametinib: mercado anual potencial de $ 180 millones
• Nirogacestat: potencial de ventas máximo estimado de $ 500 millones

Acuerdos de licencia

Los acuerdos de licencia actuales generan flujos de ingresos con potencial total de $ 215.3 millones.

Subvenciones de investigación y financiación del gobierno

Fuente de financiación	Cantidad	Año
NIH Subvenciones	$ 12.5 millones	2023
Programas SBIR/STTR	$ 3.2 millones	2023

Ingresos de regalías potenciales de las terapias desarrolladas

Los ingresos estimados de regalías varían desde 8% a 15% para desarrollos terapéuticos con licencia, con potencial de regalías anual proyectado de $ 45.6 millones.

SpringWorks Therapeutics, Inc. (SWTX) - Canvas Business Model: Value Propositions

The core value SpringWorks Therapeutics, Inc. delivers centers on providing the first or only approved systemic treatments for specific, devastating rare diseases and cancers, often with an oral administration advantage.

First and only FDA-approved systemic therapy for adult desmoid tumors (OGSIVEO)

OGSIVEO (nirogacestat) is an oral gamma secretase inhibitor approved for adults with progressing desmoid tumors who require systemic treatment. Long-term follow-up data from the Phase 3 DeFi trial, utilizing a December 2024 data cutoff, showed that continuous treatment was associated with deepening responses.

The efficacy profile includes:

• Objective Response Rate (ORR) improved to 45.7% with up to four years of treatment.
• This ORR comprised 34.3% Partial Responses (PRs) and 11.4% Complete Responses (CRs) in total.
• Median best percent reduction in target tumor size reached -75.8% for patients completing at least four years of treatment.
• The median duration of OGSIVEO treatment in this long-term analysis was 33.6 months.

The U.S. commercial execution for OGSIVEO generated preliminary fourth quarter 2024 net product revenue of $61.5 million, leading to full-year 2024 U.S. net product revenues of $172.0 million.

First and only FDA-approved therapy for adult and pediatric NF1-PN (GOMEKLI)

GOMEKLI (mirdametinib) received FDA approval on February 11, 2025, for adult and pediatric patients aged 2 years and older with symptomatic plexiform neurofibromas (PN) not amenable to complete resection. This made it the first and only medicine approved for both adults and children with NF1-PN. Neurofibromatosis type 1 (NF1) affects approximately 100,000 children and adults in the United States, with approximately 40,000 living with NF1-PN. Historically, up to approximately 85% of these tumors could not be completely resected.

The value delivered in the Phase 2b ReNeu trial is quantified below:

Metric	Adult Patients (N=58)	Pediatric Patients (N=56)
Confirmed Objective Response Rate (ORR)	41% (N=24)	52% (N=29)
Median Best % Change in Target PN Volume	-41% (Range: -90 to 13%)	-42% (Range: -91 to 48%)
Response Duration of at least 12 Months	88% of responders	90% of responders
Response Duration of at least 24 Months	50% of responders	48% of responders

Precision medicine approach targeting genetically defined rare diseases and cancers

OGSIVEO is a gamma secretase inhibitor targeting desmoid tumors. GOMEKLI is a MEK inhibitor targeting the genetic disorder NF1. SpringWorks Therapeutics also holds an exclusive license for SW-3431, a molecular glue targeting Protein Phosphatase 2A (PP2A) mutations in subsets of uterine cancer patients. The company expects to file an Investigational New Drug (IND) application for SW-3431 by the end of 2025.

Significant tumor volume reduction and symptom improvement for underserved patients

For OGSIVEO, longer-term treatment showed sustained improvement in patient-reported outcomes, including symptoms like pain. For GOMEKLI, patients experienced early and sustained significant improvements from baseline in pain and quality of life. The company ended 2024 with $461.9 million in cash, cash equivalents, and marketable securities, anticipating funding operations through profitability in the first half of 2026 (H1 2026).

Oral small molecule therapies offering patient convenience over infusions

Both approved products are administered orally. OGSIVEO is an oral gamma secretase inhibitor. GOMEKLI is an oral, small molecule MEK inhibitor. GOMEKLI is available in 1mg and 2mg capsules and a 1mg tablet for oral suspension.

SpringWorks Therapeutics, Inc. (SWTX) - Canvas Business Model: Customer Relationships

You're building relationships in a space where every patient matters, and that means the connection has to be deep, not just wide. For SpringWorks Therapeutics, Inc. (SWTX), the customer relationship strategy centers on precision and high-touch support, especially given the rare nature of the diseases they target.

High-touch, specialized sales and medical affairs teams for rare disease centers

The commercial structure is built around specialized expertise. As of early 2025, the company had onboarded 35 territory business managers, all possessing deep oncology and rare disease experience, which is key for building credibility quickly. This team's initial focus for a newly approved therapy like GOMEKLI, approved in February 2025, was on preliminary physician profiling targeting approximately 70 Neurofibromatosis Clinical Network (NFCN) centers and other key sites across the U.S.. This targeted approach ensures that the limited, specialized sales and medical affairs resources are concentrated where the patient population resides.

Direct engagement with patient advocacy and support organizations

Engagement with advocacy groups is foundational in rare disease markets. The strategy in 2025 emphasizes working directly with these organizations to support health literacy initiatives and co-create educational content. This is a necessary step to reach the estimated U.S. patient populations: approximately 30,000 adult NF1-PN patients and 10,000 pediatric NF1-PN patients who have significant unmet need.

Dedicated patient support programs for access and reimbursement assistance

For a commercial-stage company, access is everything, especially with high-value, specialized therapies. SpringWorks Therapeutics designed robust patient service offerings to facilitate rapid access and support the treatment experience. While specific program enrollment numbers for late 2025 aren't public, the context is clear: the company is managing the commercialization of OGSIVEO, which achieved $61.5 million in U.S. net product revenue in the third quarter of 2024, and is launching its second product. The relationship here is transactional but heavily supported by assistance programs designed to overcome financial and logistical barriers for patients.

Relationship management with key opinion leaders (KOLs) and oncologists

Managing relationships with Key Opinion Leaders (KOLs) has evolved beyond just conference presentations. In 2025, the focus is on continuous, strategic engagement. This includes utilizing platforms for virtual advisory boards and digital co-publication workflows to capture ongoing feedback. The goal is to evolve the relationship from transactional to strategic, using KOL insights to shape educational strategy. For instance, market research indicated that 91% of surveyed oncologists believed a new therapy would become a standard of care within 12 months of its approval.

Here's a quick view of the relationship focus areas and relevant scale metrics as of late 2025:

Relationship Focus Area	Key Metric/Target Population	Latest Relevant Financial/Volume Data
Specialized Sales Force Deployment	35 Territory Business Managers Onboarded	N/A (Focus on specialized reach)
Targeted Treatment Centers	Initial focus on ~70 NFCN centers in the U.S.	N/A (Focus on center density)
Targeted NF1-PN Patient Pool (U.S.)	~30,000 Adult Patients; ~10,000 Pediatric Patients	N/A (Focus on patient need)
KOL Engagement Model	Continuous engagement via virtual advisory boards and digital workflows	91% of surveyed oncologists expected new therapy to become standard of care within 12 months
Commercial Success Context (OGSIVEO)	Established standard of care for Desmoid Tumors	$61.5 million U.S. Net Product Revenue in 3Q 2024

The company's overall revenue growth rate of 133.70% provides the financial backdrop supporting the investment in these high-touch relationships, even as the company projected profitability in the first half of 2026.

• The commercial team is built to support the launch of the second medicine in 2025.
• The strategy prioritizes building trust through education and access support.
• The company is committed to sharing scientific presentations at medical congresses to build scientific relationships.
• The relationship management must support the global expansion following the European Commission approval of OGSIVEO in August 2025.

SpringWorks Therapeutics, Inc. (SWTX) - Canvas Business Model: Channels

You're looking at how SpringWorks Therapeutics, Inc. moved its specialized medicines from the lab bench to the patient's hands, especially as the company transitioned under new ownership in 2025. The channels strategy centered on high-touch, specialized access for rare tumor patients.

Specialty pharmacies and distributors for drug delivery in the U.S.

For U.S. drug delivery, the focus was on specialty channels equipped to handle complex therapies like OGSIVEO (nirogacestat) and GOMEKLI (mirdametinib). Onco360, for instance, was selected as a national pharmacy partner specifically for GOMEKLI (mirdametinib) as of February 2025.

• Onco360 selected as national pharmacy partner for GOMEKLI (mirdametinib) in February 2025.
• Hospitals and clinics represent a significant channel for specialty drug distribution, requiring specialized infrastructure.

The broader U.S. specialty drug distribution market, where these channels operate, is heavily weighted toward oncology:

Metric	Value/Percentage	Context/Source Year
Oncology Segment Share of Specialty Drug Distribution Market	Over 50%	Global Market Share
North America Share of Global Specialty Drug Distribution Market	Approximately 55%	Global Market Share

Direct sales force targeting rare tumor specialists and oncology centers

The commercialization effort required a focused sales team to reach the small, specific population of rare tumor specialists treating conditions like desmoid tumors and NF1-PN. This specialized targeting is inherent in the company's focus on rare oncology, where patients can't wait.

• The company's rare tumor portfolio targets conditions like desmoid tumors and NF1-PN.
• The business combination with Merck KGaA, Darmstadt, Germany, was valued at an enterprise value of $3.4 billion (€3.0 billion) as of the closing in July 2025, reflecting the value of the U.S. commercial success built on these specialized channels.

Global commercial network of Merck KGaA for international expansion

The acquisition by Merck KGaA, Darmstadt, Germany, finalized in July 2025 for an enterprise value of $3.4 billion, immediately activated a global commercial network. This was a key channel strategy shift for international reach beyond the U.S. launch success.

• Acquisition closed July 1, 2025, for an enterprise value of $3.4 billion.
• The deal is expected to be accretive to Merck KGaA's EPS pre by 2027.
• OGSIVEO (nirogacestat) received a positive opinion from the EMA's CHMP in June 2025, paving the way for European market access.
• EZMEKLY (mirdametinib) received conditional approval from the European Commission in July 2025 for adult and pediatric patients with NF1-PN.

Peer-reviewed publications and medical conference presentations (e.g., ASCO)

Scientific dissemination through key medical channels validates the products and informs prescribing patterns among specialists. SpringWorks Therapeutics actively presented data throughout 2025.

Conference/Publication	Date	Product/Data Focus
Journal of Clinical Oncology Publication	October 21, 2025	Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat)
European Society for Medical Oncology Annual Congress	October 17- 21, 2025	Encore data presentation for Nirogacestat.
Connective Tissue Oncology Society (CTOS) Congress	November 12-17, 2025	Post Hoc Analyses of the Phase 3 DeFi Trial of Nirogacestat.
European Society for Medical Oncology Sarcoma and Rare Cancers Annual Congress	March 20-22, 2025	Oral presentation on Long-term Nirogacestat Treatment in Adult Patients With Desmoid Tumors.

The company's commitment to sharing science means they were presenting at major venues, like the European Society for Medical Oncology Annual Congress in October 2025, and the CTOS Congress in November 2025. That's how you build credibility in a niche market, defintely.

SpringWorks Therapeutics, Inc. (SWTX) - Canvas Business Model: Customer Segments

You're looking at the core patient populations that drive the revenue engine for SpringWorks Therapeutics, Inc. (SWTX) as of late 2025. This isn't just about one drug; it's about two distinct, high-need rare disease communities where SWTX has established itself as a first-mover or a strong challenger.

Adult Patients with Progressing Desmoid Tumors Requiring Systemic Treatment

This segment is the initial commercial base for OGSIVEO (nirogacestat), which became the first FDA-approved drug for this indication in November 2023. The market is niche but underserved, which allowed for rapid establishment as the systemic standard of care. By the end of 2024, OGSIVEO had already generated preliminary U.S. net product revenue of $172.0 million since its launch. Annually, between 900 and 1,500 people in the United States are newly diagnosed with a desmoid tumor. The European market is also opening up; the European Commission granted marketing authorization for OGSIVEO in August 2025, making it the first and only approved therapy in the European Union (EU) for this condition.

Adult and Pediatric Patients with Symptomatic NF1-PN Not Amenable to Complete Resection

This segment is targeted by GOMEKLI (mirdametinib), which gained FDA approval in February 2025, making it the first and only medicine approved for both adults and children with symptomatic NF1-PN not amenable to complete resection. In the U.S., there are an estimated 40,000 people living with NF1-PN. Critically, adults make up about 75% of this patient population, a group previously managed only with off-label therapies or surgery. The pivotal Phase 2b ReNeu trial that supported this approval enrolled 114 patients in total: 58 adults and 56 pediatric patients aged 2 years and older.

Here's a quick math on the target populations for the two commercial assets:

Indication	Drug	U.S. Patient Estimate	Key Demographic Split	2024 Revenue (USD)
Progressing Desmoid Tumors	OGSIVEO	900 to 1,500 new diagnoses annually	Adults requiring systemic treatment	$172.0 million (FY 2024 Net Product Revenue)
Symptomatic NF1-PN	GOMEKLI	Approximately 40,000 total patients	Adults represent approximately 75%	N/A (Approved Feb 2025)

Oncologists and Rare Tumor Specialists Prescribing OGSIVEO and GOMEKLI

The adoption curve for these specialized therapies depends heavily on key prescribers. For GOMEKLI, initial commercial efforts focused on building relationships within specialized centers. Management indicated an initial focus on approximately 70 NFCN (Neurofibromatosis Clinical Network) centers and other key sites in the U.S. as of January 2025. For OGSIVEO, the launch success was supported by an 'enthusiastic prescriber base' showing a strong preference for the drug early in 2025. These specialists are the gatekeepers to the patient pools.

Academic and Industry Partners for Combination Therapy Trials

SpringWorks Therapeutics, Inc. is actively expanding the utility of its molecules through external collaborations, which broadens the potential customer base beyond the initial rare disease indications. This is particularly true for OGSIVEO (nirogacestat) in oncology settings. The company continues to support several industry and academic collaborator studies evaluating nirogacestat as part of BCMA (B-cell maturation antigen) combination therapy regimens for patients with multiple myeloma.

The key external players involved in clinical development, including those for nirogacestat, include:

• Academic Collaborators like the Children's Oncology Group (COG) for a Phase 2 trial in pediatric desmoid tumors.
• Industry partners for preclinical, Phase 1, and Phase 2 studies involving nirogacestat, such as GSK, Janssen, Pfizer, Regeneron, and AbbVie.
• The planned acquisition by Merck KGaA in April 2025 solidifies a major industry relationship, aligning SWTX's rare tumor portfolio with Merck's broader healthcare strategy.

Finance: draft 13-week cash view by Friday.

SpringWorks Therapeutics, Inc. (SWTX) - Canvas Business Model: Cost Structure

The cost structure for SpringWorks Therapeutics, Inc. is heavily weighted toward operating expenses supporting commercialization and pipeline progression as of late 2025. The primary cost drivers are Selling, General, and Administrative (SG&A) and Research and Development (R&D) activities.

Expense Category	Q1 2025 Amount (Millions USD)
Selling, General, and Administrative (SG&A)	$76.5
Research and Development (R&D)	$49.6
Milestone Payment to Pfizer	$6.0

High Selling, General, and Administrative (SG&A) expenses totaled $76.5 million in Q1 2025. This increase was driven by commercial launches.

Significant Research and Development (R&D) expenses were $49.6 million in Q1 2025, focused on pipeline advancement.

The company incurred costs associated with manufacturing and supply chain for two commercial products.

Milestone payments to partners included a $6.0 million payment to Pfizer in Q1 2025.

Costs related to global regulatory filings and post-marketing commitments are also a component of the structure.

Additional financial context for Q1 2025 operating costs includes:

• Net loss of $83.2 million.
• Net cash used in operating activities of $68.8 million.
• Cash, cash equivalents, and marketable securities balance of $382.7 million as of March 31, 2025.

The commercial success of the two products contributed to revenue, but also to the operating expense base. OGSIVEO generated $44.1 million in Q1 2025 revenue, and GOMEKLI contributed $4.9 million following its U.S. launch in February 2025.

Future R&D commitments include an expected IND filing for SW-3431 by the end of 2025.

Finance: draft 13-week cash view by Friday.

SpringWorks Therapeutics, Inc. (SWTX) - Canvas Business Model: Revenue Streams

You're looking at the top-line drivers for SpringWorks Therapeutics, Inc. as of late 2025. The revenue streams are heavily weighted toward the commercial success of their two approved products, supplemented by potential non-recurring events like voucher monetization and contractual milestones.

The immediate, tangible revenue comes from product sales, which showed significant growth early in the year. For the first quarter of 2025, the combined net product revenue hit $49.1 million.

Here's the quick math on the product revenue breakdown for Q1 2025:

Product	Q1 2025 Net Product Revenue
OGSIVEO (nirogacestat)	$44.1 million
GOMEKLI (mirdametinib)	$4.9 million

Looking ahead, the market consensus for the full fiscal year 2025 revenue is set at approximately $330.84 million. That figure incorporates the expected ramp-up for both OGSIVEO and the initial contribution from GOMEKLI, which received its FDA approval in February 2025.

Beyond product sales, SpringWorks Therapeutics has other important, albeit less predictable, revenue components:

• Milestone payments and royalties from licensing agreements, such as the initial arrangement with Pfizer, which entitles Pfizer to undisclosed payments tied to clinical development milestones and royalties on sales of approved products.
• Potential revenue from the monetization of the Rare Pediatric Disease Priority Review Voucher (PRV).
• Other potential milestone payments from out-licensed assets, like the FAAH inhibitor program, which could yield up to $375.0 million in potential milestone payments plus incremental tiered royalties in the mid- to high-single digit percentages on future net sales of that specific asset.

The Rare Pediatric Disease Priority Review Voucher (PRV) is a key non-recurring asset. SpringWorks Therapeutics received this voucher following the February 11, 2025, FDA approval of GOMEKLI (mirdametinib) for symptomatic NF1-PN. While the program itself expired at the end of 2024, GOMEKLI's approval qualified the company to receive one. These vouchers are highly valuable; for instance, recent comparable sales have been reported in the range of $150 million to $155 million, representing a significant, one-time cash infusion opportunity if SpringWorks Therapeutics chooses to sell it rather than redeem it for an expedited review of a future product.

So, you've got the core product sales, the full-year projection, and the potential upside from contractual milestones and the PRV. Finance: draft 13-week cash view by Friday.